<DOC>
<DOCNO>EP-0640612</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Novel derivatives from 2-(1H)-quinolinone, process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31675	A61P2518	A61P2508	C07F960	A61K31675	A61P4300	A61P4300	C07F9576	C07F900	A61P2500	A61P2528	A61P2500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	A61P	C07F	A61K	A61P	A61P	C07F	C07F	A61P	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61P25	A61P25	C07F9	A61K31	A61P43	A61P43	C07F9	C07F9	A61P25	A61P25	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I): 
<
IMAGE
>
  in which:   R1, R2 and R3, which are identical or different, represent a hydrogen or halogen atom or an alkyl, nitro, cyano or aminosulphonyl group or else, when two of them are situated on adjacent carbons, form, with the carbon atoms to which they are attached, a (C3-C7)cycloalkyl ring or a benzene ring which is substituted or unsubstituted, R4 represents a hydrogen atom, a substituted or unsubstituted phenyl or linear or branched (C1-C6)alkyl group or a group 
<
IMAGE
>
 in which R6 or R7, which are identical or different, represent a hydrogen atom or a substituted or unsubstituted, linear or branched (C1-C6)alkyl group, R5 represents a hydrogen atom, a hydroxyl, linear or branched (C1-C6)alkoxy, phenoxy, mercapto, linear or branched (C1-C6)alkylthio, substituted or unsubstituted, linear or branched (C1-C6)alkyl, substituted or unsubstituted phenyl or substituted or unsubstituted amino group, or a group 
<
IMAGE
>
  in which R6 or R7 are as defined above, their isomers and their addition salts with a pharmaceutically acceptable acid or base. Medicaments.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ADIR
</APPLICANT-NAME>
<APPLICANT-NAME>
ADIR ET COMPAGNIE
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CORDI ALEX
</INVENTOR-NAME>
<INVENTOR-NAME>
DESOS PATRICE
</INVENTOR-NAME>
<INVENTOR-NAME>
LEPAGNOL JEAN
</INVENTOR-NAME>
<INVENTOR-NAME>
CORDI, ALEX
</INVENTOR-NAME>
<INVENTOR-NAME>
DESOS, PATRICE
</INVENTOR-NAME>
<INVENTOR-NAME>
LEPAGNOL, JEAN
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of formula (I) :


wherein :

R
1
 R
2
 and R
3
,
which are identical or different, each represents a hydrogen atom, a
halogen atom, a linear or branched (C
1
-C
6
)-alkyl group (unsubstituted or
substituted by one or more halogen atoms), or a nitro, cyano or aminosulphonyl

group,

or, when two of those radicals are located at adjacent carbon atoms, those two
radicals form with the carbon atoms to which they are attached a (C
3
-C
7
)-cycloalkyl
ring or a benzene ring (unsubstituted or substituted by one or more

halogen atoms, linear or branched (C
1
-C
6
)-alkyl groups, linear or branched
(C
1
-C
6
)-alkoxy groups or trihalomethyl groups),
R
4
represents a hydrogen atom, a linear or branched (C
1
-C
6
)alkyl group, a phenyl
group (unsubstituted or substituted by one or more halogen atoms, linear or

branched (C
1
-C
6
)-alkyl groups, linear or branched (C
1
-C
6
)-alkoxy groups or
trihalomethyl groups) or a grouping



wherein R
6
 and R
7
,
which are identical or different, each represents a hydrogen atom or a linear or

branched (C
1
-C
6
)-alkyl group (unsubstituted or substituted by a (C
3
-C
7
)-cycloalkyl
group or phenyl group),
R
5
represents a hydrogen atom, or one of the following groups: hydroxy, linear or
branched (C
1
-C
6
)-alkoxy, phenoxy, mercapto, linear or branched (C
1
-C
6
)-alkylthio,
linear or branched (C
1
-C
6
)-alkyl (unsubstituted or substituted by a
(C
3
-C
7
)-cycloalkyl group), phenyl (unsubstituted or substituted by one or more
halogen atoms, linear or branched (C
1
-C
6
)-alkyl groups, linear or branched
(C
1
-C
6
)-alkoxy groups or trihalomethyl groups) or amino (unsubstituted or 
substituted by one or two linear or branched (C
1
-C
6
)-alkyl groups) or a grouping


wherein

R
6
 and R
7
 are as defined above,

their isomers and the additions salts thereof with a pharmaceutically acceptable acid
or base.
Compounds of formula (I) according to claim 1 wherein at least one of the groups
R
1
, R
2
 and R
3
 represents a chlorine atom.
Compounds of formula (I) according to claim 1 wherein R
4
 represents a hydrogen
atom.
Compounds of formula (I) according to claim 1 wherein R
5
 represents a hydroxy
group.
Compound of formula (I) according to claim 1 which is 6,7-dichloro-2(1H)-quinolinone-3-phosphonic
acid.
Process for the preparation of compounds of formula (I) according to claim 1,
characterised in that there is used as starting material a compound of formula (II):



wherein R
1
, R
2
 and R
3
 are as defined for formula (I),

which is reduced, in accordance with the nature of the substituents R
1
, R
2
 and R
3
,
either in aprotic medium in the presence of lithium aluminium hydride, aluminium

hydride, diborane or complexes of borane,

or in protic acid medium when sodium cyanoborohydride is used,

to yield an alcohol of formula (III) :

 
wherein R
1
, R
2
 and R
3
 are as defined for formula (I),

which is oxidised by means of a metal oxide in an inert solvent, a hydrohalogenate of
an alkali metal in a protic solvent or an acid chloride in dimethyl sulphoxide,

to yield an aldehyde of formula (IV) :


wherein R
1
, R
2
 and R
3
 are as defined for formula (I),

which is then condensed with an alkyl malonate of formula (V):


wherein alk represents a linear or branched (C
1
-C
6
)-alkyl group, in protic medium in
the presence of an alkali metal alcoholate, a tertiary amine or an alkali metal

hydroxide,

to yield an ester of formula (VI) :


wherein R
1
, R
2
, R
3
 and alk are as defined above,

which is converted into the corresponding acid of formula (VII) :


wherein R
1
, R
2
 and R
3
 are as defined for formula (I),

which is reacted in the presence of bromine in pyridine to yield a compound of
formula (VIII): 



wherein R
1
, R
2
 and R
3
 are as defined for formula (I),

the lactam function of which is protected by the action of phosphorus oxychloride
followed by the action of an alkali metal alcoholate in alcoholic medium, to yield a

compound of formula (IX) :


wherein R
1
, R
2
 and R
3
 are as defined for formula (I) and R represents a linear or
branched (C
1
-C
6
)-alkyl group,

which is reacted with a dialkyl or diaryl phosphite in anhydrous medium, in the

presence of triethylamine and tetrakis(triphenylphosphine)palladium as catalyst, to
yield a compound of formula (X) :



wherein R
1
, R
2
, R
3
 and R are as defined above and R'
4
 represents a linear or branched
(C
1
-C
6
)-alkyl group or an aryl group, which is then:

either
fully deprotected in the presence of trimethylsilane bromide in acetonitrile
medium and then treated in acid medium,

to yield a compound of formula (I/a), a particular case of compounds of
formula (I) :



wherein R
1
, R
2
 and R
3
 are as defined for formula (I),
 
which, if desired, is reacted in basic medium with a halogenated compound

of formula R"
4
-Cl wherein R"
4
 represents a linear or branched (C
1
-C
6
)-alkyl
group, a phenyl group (unsubstituted or substituted by one or more halogen

atoms, linear or branched (C
1
-C
6
)-alkyl groups, linear or branched (C
1
-C
6
)-alkoxy
groups or trihalomethyl groups)

or a grouping


wherein R
6
 and R
7
 are as defined for
formula (I),

to yield a compound of formula (I/b), a particular case of compounds of
formula (I)



wherein R
1
, R
2
, R
3
 and R"
4
 are as defined above,
or
partially deprotected by treatment in basic medium to yield a compound of
formula (XI) :



wherein R
1
, R
2
, R
3
, R and R'
4
 are as defined above,
which compound of formula (XI)
:

depending on the nature of the compounds of formula (I) it is desired to obtain is
subjected


to treatment in acid medium to yield a compound of formula (I/c), a particular
case of compounds of formula (I):



wherein R
1
, R
2
, R
3
 and R'
4
 are as defined above, 
to the action of an alcohol of formula (XII):

R'
5
-OH

wherein R'
5
 represents a linear or branched (C
1
-C
6
)-alkyl group or a phenyl
group, to yield a compound of formula (XIII) :



which is selectively deprotected by the action of trimethylsilane bromide in
acetonitrile medium followed by treatment with hydrochloric acid, to yield a

compound of formula (I/d), a particular case of compounds of formula (I) :


wherein R
1
, R
2
, R
3
 and R'
5
 are as defined above,
or to the action of oxalyl chloride, to yield a compound of formula (XIV) :


wherein R
1
, R
2
, R
3
, R and R'
4
 are as defined above,
which compound of formula (XIV)
 is then:

either treated in anhydrous medium with an organomagnesium compound
of formula (XV):


R"
5
MgX

wherein X represents a halogen atom and R"
5
 represents a linear or
branched (C
1
-C
6
)-alkyl group (unsubstituted or substituted by a (C
3
-C
7
)-cycloalkyl
group) or a phenyl group (unsubstituted or substituted by one or

more halogen atoms, linear or branched (C
1
-C
6
)-alkyl groups, linear or 
branched (C
1
-C
6
)-alkoxy groups or trihalomethyl groups) to yield a
compound of formula (XVI) :



wherein R
1
, R
2
, R
3
, R, R'
4
 and R"
5
 are as defined above,

which is deprotected by the action of trimethylsilane bromide in acetonitrile
medium followed by treatment with hydrochloric acid,

to yield a compound of formula (I/e), a particular case of compounds of
formula (I) :



wherein R
1
, R
2
, R
3
 and R"
5
 are as defined above,
or reacted with a hydride, H
2
S, alkSH (wherein alk denotes a linear or
branched (C
1
-C
6
)-alkyl group) or ammonia, to yield a compound of formula
(XVII) :



wherein R
1
, R
2
, R
3
, R and R'
4
 are as defined above and R' represents HS-,
alkS- or H
2
N-, or a hydrogen atom,

which is deprotected by the action of trimethylsilane bromide in acetonitrile
medium followed by treatment with hydrochloric acid,

to yield a compound of formula (I/f), a particular case of compounds of
formula (I):


 
wherein R
1
, R
2
, R
3
 and R' are as defined above,

which compound of formula (I/a), (I/b), (I/c), (I/d), (I/e) or (I/f),

when R
1
 and/or R
2
 and/or R
3
 represent a hydrogen atom, may be subjected to
electrophilic substitutions according to conventional aromatic nuclei

substitution techniques yielding a compound of formula (I) mono-, di- or trisubstituted
at the phenyl nucleus of the quinolinone,
when R
1
 and/or R
2
 and/or R
3
 represent a nitro group, may be subjected to
hydrogenation to yield the corresponding amino compound which in turn may,

if desired, by converted into the corresponding cyano compound,
may, if necessary, be purified according to a conventional purification
technique.
is separated, if appropriate, into its isomers according to a conventional
separation technique,
is converted, if desired, into its addition salts with a pharmaceutically
acceptable acid or base.
Pharmaceutical compositions containing as active ingredient at least one compound
according to any one of claims 1 to 5, alone or in combination with one or more

pharmaceutically acceptable, inert, non-toxic vehicles.
Pharmaceutical compositions according to claim 7, containing at least one active
ingredient according to any one of claims 1 to 5 for use as inhibitors of pathological

phenomena associated with hyperactivation of neurotransmission pathways by
excitatory amino acids, in the treatment of cerebral vascular accident, cerebral or

spinal traumatism, epilepsy and chronic neurodegenerative disorders, such as
amyotrophic
 lateral sclerosis, Huntington's chorea, schizophrenia and Alzheimer's
disease.
</CLAIMS>
</TEXT>
</DOC>
